The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of hyperprogression in patients with sarcoma treated with targeted therapy and/or immunotherapy in early-phase clinical trials.
 
Aisha Alshibany
No Relationships to Disclose
 
Esmail Mutahar Al-Ezzi
No Relationships to Disclose
 
Abha A. Gupta
No Relationships to Disclose
 
Abdulazeez Salawu
No Relationships to Disclose
 
Geoffrey Alan Watson
Honoraria - Gilead Sciences; Pfizer
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Abbvie
 
Lisa Wang
No Relationships to Disclose
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Anna Spreafico
Honoraria - Immunocore; Medison
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Medison; Merck
Research Funding - Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Treadwell Therapeutics (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison